Journal of Vascular and Interventional Radiology
3:18 PMAbstract No. 379 - Efficacy and utilization of liver directed therapies for metastatic neuroendocrine tumors
Section snippets
Purpose
Hepatic metastases are the most common cause of mortality in patients with neuroendocrine tumors (NET). While transarterial therapies are utilized for the treatment of liver metastases from NET, their exact role within the treatment algorithm remains a matter of debate. The aim of the study is to evaluate the effect of these therapies on patient survival and their current utilization.
Materials
The California Cancer Registry was used to analyze all patients who presented with abdominal NET and hepatic metastases between 2005-2011. Patients were evaluated based upon their treatment, which included supportive care, systemic chemotherapy, liver resection or ablation, transarterial therapy (chemoembolization or radioembolization), and multimodal treatments (transarterial therapies + additional treatment). Five-year overall survival (OS) was estimated by the Kaplan-Meier method. The
Results
A total of 1029 patients with NET liver metastases were identified. Primary sites of disease were pancreas (n = 387), small bowel (n = 289), colon/rectum (n= 277), and stomach (n = 76). Hepatic metastases were documented at presentation in 86.1% of patients. Of all patients with hepatic metastases, 54.7% received treatment for metastatic disease and only 27.9% received liver-specific treatment. Treatments included chemotherapy (26.8%), liver resection (9.5%), transarterial therapy (14.5%) and
Conclusions
Liver targeted therapies improve survival in patients with NET liver metastases. Despite the improvement in patient survival, utilization of these treatments remains low.